PHARMA REPACKAGING BATTLE GOES BACK TO LUXEMBOURG

The battle between drugs giants Boehringer Ingelheim, Glaxo and Eli Lilly against parallel importers Dowelhurt and Swingward has been fought out keenly in the UK courts, having been referred to the European Court of Justice some years ago for a reference as to the extent to which the relabelling, over-stickering and repackaging of trade mark-protected pharma products was justifiable as being objectively necessary. Perhaps not surprisingly, this huge case is in the news again. The Court of Appeal for England and Wales has just sent the case back to Brussels for a further reference.

The IPKat will tell you what it's all about once he's had the chance to read it and ponder, so watch this space.
PHARMA REPACKAGING BATTLE GOES BACK TO LUXEMBOURG PHARMA REPACKAGING BATTLE GOES BACK TO LUXEMBOURG Reviewed by Jeremy on Monday, March 08, 2004 Rating: 5

No comments:

All comments must be moderated by a member of the IPKat team before they appear on the blog. Comments will not be allowed if the contravene the IPKat policy that readers' comments should not be obscene or defamatory; they should not consist of ad hominem attacks on members of the blog team or other comment-posters and they should make a constructive contribution to the discussion of the post on which they purport to comment.

It is also the IPKat policy that comments should not be made completely anonymously, and users should use a consistent name or pseudonym (which should not itself be defamatory or obscene, or that of another real person), either in the "identity" field, or at the beginning of the comment. Current practice is to, however, allow a limited number of comments that contravene this policy, provided that the comment has a high degree of relevance and the comment chain does not become too difficult to follow.

Learn more here: http://ipkitten.blogspot.com/p/want-to-complain.html

Powered by Blogger.